leisure time -WSS

leisure time

author：hotspot 2025-10-01 02:13:46 - browse：4215

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： STAT wants to know your pick for a great summer read or listen

leisure time

entertainment

WSS

Four alarming medical procedures we’re glad history forgot

Republican states more likely to report Covid vaccine side effects

Drug cartel violence flares in western Mexico after vigilante leader's killing

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Republican states more likely to report Covid vaccine side effects

Researchers test human milk's ability to repair gut microbiome

hotspot

leisure time

knowledge

Alkermes shareholders re

Beware reading your test results before your doctor does

Affirmative action in medical school literally saved lives

Insurer loopholes limit power of law against surprise medical bills

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

As demand for Covid shots wanes, Moderna seeks its next success

Oral obesity drug from Viking Therapeutics hits key early target

How to save PrEP access — and even expand it

Undocumented workers face uncertainty as immigration law takes effect in Florida

hotspot

UpToDate has a racism problem: Dr. Stanley Goldfarb

Multiple sclerosis has subtypes with different best treatments: study

Security flaws in third

Scientists uncover potential path to treating deadly childhood tumor

What affirmative action's end means to a medical student

Fatty liver disease was alleviated by Lilly’s ‘triple

leisure time

focus

entertainment

knowledge